• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

haskali.m@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-3084-2084

Dr Mo Haskali

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

105 Scholarly works
4 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer
    DOI: 10.1186/s13046-026-03659-w
  • 2026

    Journal article

    Identification of Aldosterone-Producing Adrenal Adenomas Using [68Ga]Ga-Pentixafor PET/CT in an Australian Cohort
    DOI: 10.2967/jnumed.125.271006
  • 2026

    Journal article

    P0350 Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial
    DOI: 10.1016/s0302-2838(26)01246-7
  • 2026

    Journal article

    Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
    DOI: 10.1039/d6ra90008a
  • 2023

    Research grants (international)

    An Accelerated Platform Using Lead-212 Targeted \03b1-Particle Therapy to Radically Improve Cancer Lethality of Prostate Cancer Theranostics Using Novel Targets and Better Understanding of Resistance: The Cancer Lethality Lead Collaboration
  • 2022

    Research grants (other domestic)

    Investigating a New Strategy for Diagnosis and Personalised Treatment of Hormone Positive Metastatic Breast Cancer Using Dual Purpose Theranostics Targeting the Neuropeptide Y-1 Receptor
  • 2019

    Research Grant

    Development of Innovative Foldamers for the Peptide Receptor Radionuclide Therapy of Tumours Overexpressing Cholecystokinin-2 Receptors
Mo Haskali

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
    DOI: 10.1039/d5ra08789a
  • 2026

    Journal article

    Early microglia-mediated neuroinflammation after status epilepticus causes behavioral dysfunction and neurocognitive deficits but not epilepsy in mice
    DOI: 10.1016/j.bbi.2025.106183
  • 2026

    Journal article

    A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents
    DOI: 10.1038/s41596-025-01176-2
  • 2025

    Journal article

    Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters
    DOI: 10.1186/s41181-025-00372-5
  • 2025

    Conference Proceedings

    Radiolabelled peptides targeting CXCR4 for cancer imaging and treatment
    DOI: 10.1016/j.nucmedbio.2025.109419
  • 2025

    Conference Proceedings

    Dual Function, Singular Impact: Successes of a Novel Class of Theranostic Gastramide (GA) Peptides Targeting Cholecystokinin-2 Receptor
    DOI: 10.1016/j.nucmedbio.2025.109530

RECENT PROJECTS

  • 2025

    Research grants (other domestic)

    Testing Alternate Therapeutic Strategies for Bone Metastatic Prostate Cancer

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224